Skip to main content

Commercial feasibility of microbial therapy

Objective

Our body is colonized by complex microbial communities (our microbiome) that are most abundant in the intestinal tract where they contribute significantly to our health and disease. It has been established that aberrations in our microbiome are of particular importance in obesity, type 2 diabetes and metabolic syndrome, rapidly growing diseases with a drug market volume of over 5 B$ per year. We have discovered in the ERC project Microbes Inside that a particular bacterium is able to modify the intestinal microbiome and may be used to develop a new approach to treat these and other metabolic diseases. The Proof of Concept project ACOM aims to confirm the commercial and technological feasibility of this approach, consolidate and expand our IP position, and develop a product development plan. These form the elements of a business plan that is expected to result in establishing a spin out company (ACOM).

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/clinical medicine/endocrinology/diabetes
  • /social sciences/economics and business

Call for proposal

ERC-2013-PoC
See other projects for this call

Funding Scheme

CSA-SA(POC) - Supporting action (Proof of Concept)

Host institution

WAGENINGEN UNIVERSITY
Address
Droevendaalsesteeg 4
6708 PB Wageningen
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 142 000
Administrative Contact
Tom Bessems (Mr.)

Beneficiaries (1)

WAGENINGEN UNIVERSITY
Netherlands
EU contribution
€ 142 000
Address
Droevendaalsesteeg 4
6708 PB Wageningen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tom Bessems (Mr.)